针对H10N8和H7N9流感病毒的mRNA疫苗1期试验免疫原性与耐受性
两项随机、安慰剂对照、双盲1期试验在健康成人中评估首款H10N8和H7N9 mRNA疫苗。疫苗总体安全耐受,未报告疫苗相关严重不良事件,并诱导了较强的体液免疫应答;未检测到显著细胞免疫应答。
要点
- H10N8 mRNA疫苗100µg肌内注射使100%受试者HAI滴度≥1:40,87.0%受试者MN滴度≥1:20。
- H7N9 mRNA疫苗25µg肌内注射使96.3%受试者HAI滴度≥1:40,10和25µg组MN滴度≥1:20均达100%。
- 两项研究均未报告疫苗相关严重不良事件,但未检测到显著细胞免疫应答。
核心结论
- 首款针对H10N8和H7N9流感病毒的mRNA疫苗耐受性良好,并诱导了较强的体液免疫应答。
研究设计与样本
- H10N8研究入组18-64岁成人(N=201),H7N9研究入组18-49岁成人(N=156)。
- 受试者接受2剂疫苗或安慰剂,间隔3周;H7N9另评估间隔6个月的2剂程序。
- H10N8肌内注射剂量为25、50、75、100和400µg,皮内注射剂量为25和50µg;H7N9肌内注射剂量为10、25和50µg。
主要发现
- H10N8 100µg肌内注射组100%受试者HAI滴度≥1:40,87.0%受试者MN滴度≥1:20。
- H10N8 25µg皮内注射组64.7%受试者HAI滴度>1:40,肌内注射组为34.5%。
- H7N9 10、25和50µg肌内注射组HAI滴度≥1:40的比例分别为36.0%、96.3%和89.7%。
- H7N9 10和25µg组MN滴度≥1:20均达100%,50µg组为96.6%。
- H10N8 100µg肌内注射组血清转化率HAI 78.3%、MN 87.0%;H7N9 50µg组HAI 96.3%、MN 100%。
临床怎么用
- 提示mRNA平台可用于大流行潜力禽流感疫苗的快速开发,但需进一步2/3期试验确认保护效力。
局限性
- 两项均为1期小样本单中心试验,仅评估安全性和免疫原性,未评估临床保护效力。
- 未检测到显著细胞免疫应答,体液免疫应答的持久性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated safety and immunogenicity of the first mRNA vaccines against potentially pandemic avian H10N8 and H7N9 influenza viruses. METHODS: Two randomized, placebo-controlled, double-blind, phase 1 clinical trials enrolled participants between December 2015 and August 2017 at single centers in Germany (H10N8) and USA (H7N9). Healthy adults (ages 18-64 years for H10N8 study; 18-49 years for H7N9 study) participated. Participants received vaccine or placebo in a 2-dose vaccination series 3 weeks apart. H10N8 intramuscular (IM) dose levels of 25, 50, 75, 100, and 400 µg and intradermal dose levels of 25 and 50 µg were evaluated. H7N9 IM 10-, 25-, and 50-µg dose levels were evaluated; 2-dose series 6 months apart was also evaluated. Primary endpoints were safety (adverse events) and tolerability. Secondary immunogenicity outcomes included humoral (hemagglutination inhibition [HAI], microneutralization [MN] assays) and cell-mediated responses (ELISPOT assay). RESULTS: H10N8 and H7N9 mRNA IM vaccines demonstrated favorable safety and reactogenicity profiles. No vaccine-related serious adverse event was reported. For H10N8 (N = 201), 100-µg IM dose induced HAI titers ≥ 1:40 in 100% and MN titers ≥ 1:20 in 87.0% of participants. The 25-µg intradermal dose induced HAI titers > 1:40 in 64.7% of participants compared to 34.5% of participants receiving the IM dose. For H7N9 (N = 156), IM doses of 10, 25, and 50 µg achieved HAI titers ≥ 1:40 in 36.0%, 96.3%, and 89.7% of participants, respectively. MN titers ≥ 1:20 were achieved by 100% in the 10- and 25-µg groups and 96.6% in the 50-µg group. Seroconversion rates were 78.3% (HAI) and 87.0% (MN) for H10N8 (100 µg IM) and 96.3% (HAI) and 100% (MN) in H7N9 (50 µg). Significant cell-mediated responses were not detected in either study. CONCLUSIONS: The first mRNA vaccines against H10N8 and H7N9 influenza viruses were well tolerated and elicited robust humoral immune responses. ClinicalTrials.gov NCT03076385 and NCT03345043.
引用
- Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019. PMID: 31079849. doi:10.1016/j.vaccine.2019.04.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。